Publication | Closed Access

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

Metastatic Breast CancerOncologyBreast OncologyPhase Iii TrialClinical TrialsPatient SubgroupsBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyHealth Sciences